LYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lyra Therapeutics Inc (LYRA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, shows poor financial performance, and has no strong trading signals or favorable technical indicators. Additionally, the absence of recent news, analyst ratings, and congress trading data further diminishes its appeal.
The MACD is slightly positive at 0.042, but RSI is neutral at 48.476, providing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot point of 1.233, with resistance levels at 1.461 and 1.603. Overall, the technical indicators suggest a weak price trend.
NULL identified. No recent news, trading trends, or congress trading data to suggest a positive outlook.
The stock has an 80% chance to decline by -1.65% in the next day, -5.25% in the next week, and -0.5% in the next month. Financial performance has significantly deteriorated, with revenue, net income, and EPS all showing substantial YoY declines. Additionally, hedge funds and insiders are neutral, indicating no strong interest in the stock.
In Q3 2025, revenue dropped by -87.18% YoY to $25,000, net income fell by -49.60% YoY to -$5,984,000, and EPS declined by -62.73% YoY to -3.38. While gross margin remained at 100%, the overall financial performance is poor.
No recent analyst ratings or price target changes available for LYRA.
